Critical Management of Haemodynamically Unstable Acute Pulmonary Embolism in COVID-19
Abstract
Thrombotic events occur in up to one-third of patients with COVID-19, predominantly manifesting as pulmonary emboli (PE), which are associated with higher morbidity and mortality. Acute PE should therefore be one of the main differential diagnoses of COVID-19 patients who develop hemodynamic instability. Early systemic thrombolysis remains the first line of treatment for hemodynamically unstable PE in those infected with COVID-19, particularly considering the risks of infection to other personnel during catheter-directed thrombolysis procedures. This report aims to describe a typical case of hemodynamically unstable acute PE with COVID-19 management in our center. A 66-year-old male presented to ER with shortness of breath and desaturation was suspected of having COVID-19. Despite unremarkable physical examination, he was later confirmed to be COVID-19 positive. While in the isolation ward, he experienced a cardiac arrest. 12-lead ECG showed sign of right ventricular strain and subsequently bedside echocardiography showed a fresh thrombus in the right atria with signs of acute right ventricular dysfunction. The diagnosis of acute PE with hemodynamic instability was made, and systemic thrombolysis was immediately initiated. Despite the bleeding complication, his symptoms and hemodynamic improved and he was discharged safely with oral anticoagulant. Our case demonstrates how early recognition and prompt treatment of acute PE especially in COVID-19 patients with hemodynamic instability, can be life saving. Recognizing the subtle signs of acute PE during emergency improves patients outcome considerably.
Keywords
References
Poor HD. Pulmonary Thrombosis and Thromboembolism in COVID-19. Chest [Internet]. 2021;160(4):1471–80.
Loo J, Spittle DA, Newnham M. COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. Thorax [Internet]. 2021;76(4):412–20.
Tan BK, Mainbourg S, Friggeri A, et al. Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. Thorax [Internet]. 2021;76(10):970–9.
Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clary B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. E Clinical Medicine [Internet]. 2020;29–30:100639.
Kyriakoulis KG, Kokkinidis DG, Kyprianou IA, et al. Venous thromboembolism in the era of COVID-19. Phlebol J Venous Dis [Internet]. 2021;36(2):91–9.
Vaughn VM, Yost M, Abshire C, et al. Trends in Venous Thromboembolism Anticoagulation in Patients Hospitalized With COVID-19. JAMA Netw Open [Internet]. 2021;4(6):e2111788.
Wichmann D, Sperhake J-P, Lütgehetmann M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19. Ann Intern Med [Internet]. 2020;173(4):268–77.
Fontana P, Casini A, Robert-Ebadi H, Glauser F, Righini M, Blondon M. Venous thromboembolism in COVID-19: systematic review of reported risks and current guidelines. Swiss Med Wkly [Internet]. 2020;150:25–6.
Tal S, Spectre G, Kornowski R, Perl L. Venous thromboembolism complicated with COVID-19: What do we know so far? Acta Haematol [Internet]. 2020;143(5):417–24.
The Task Force for the management of COVID-19 of the European Society of Cardiology. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up. European Heart Journal. 2022;43:1059–103.
2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal. 2020;41:543-603.
Kollias A, Kyriakoulis KG, Lagou S, Kontopantelis E, Stergiou GS, Syrigos K. Venous thromboembolism in COVID-19: A systematic review and meta-analysis. Vasc Med [Internet]. 2021;26(4):415–25.
Gong X, Yuan B, Yuan Y. Incidence and prognostic value of pulmonary embolism in COVID-19: A systematic review and meta-analysis. Lazzeri C, editor. PLoS One [Internet]. 2022;17(3):e0263580.
Scudiero F, Pitì A, Keim R, Parodi G. Acute pulmonary embolism in COVID-19 patient: a case report of free-floating right heart thrombus successfully treated with fibrinolysis. In: Mukherjee R, Timothy C T, Nisha M, Elena S, Ross T, editors. Eur Hear J - Case Reports [Internet]. 2021;5(1):0–4.
Zhu Y-J, Zhou Y-P, Wei Y-P, et al. Association between anticoagulation outcomes and venous thromboembolism history in chronic thromboembolic pulmonary hypertension. Front Cardiovasc Med [Internet]. 2021;8:1–8.
Gavilanes-Oleas F, Alves-Jr J, Fernandes C, et al. Use of direct oral anticoagulants for chronic thromboembolic pulmonary hypertension. Clinics [Internet]. 2018;73:10–2.
Ramacciotti E, Agati LB, Calderaro D, et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet. 2022;399:50–9.
Pretorius L, AThomson GJA, Adams RCM, et al. Platelet activity and hypercoagulation in type 2 diabetes. Cardiovasc Diabetol. 2018;17:141.
Nunns GR, Moore EE, Chapman MP, et al. The hypercoagulability paradox of chronic kidney disease: The role of fibrinogen. Am J Surg. 2017;214(6): 1215–8.
Refbacks
- There are currently no refbacks.